Research and Development

At Monogram Biosciences, Inc., our mission is to improve health care by advancing individualized medicine through the discovery and commercialization of innovative products that guide and improve the treatment of serious viral infections and cancer. The company’s products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The company’s technologies are also used by pharmaceutical and biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines, as well as targeted cancer therapeutics.

We view scientific collaboration as an important component of our past and future success and the fulfillment of our mission. Since the company was founded in 1995, we have encouraged and supported productive collaborations with renowned investigators representing industry, government, and academic institutions in their diverse pursuit of basic, applied, translational, and clinical research interests. The products of these collaborations have contributed to significant advancements in the scientific and clinical understanding of antiviral drug susceptibility and resistance, viral replication, viral fitness and infectivity, antiviral immune responses and escape, viral diversity and evolution, genetic recombination, oncogene activation and transformation, cellular signal transduction, anticancer drug susceptibility and resistance, and disease prognosis.

Qualified investigators interested in establishing scientific collaborations with Monogram can inquire about collaborative opportunities or submit an online information request. Collaborative proposals will be assessed, prioritized, and approved based on the merits of the proposal using the following criteria:

  • Research plan
  • Investigator qualifications
  • Research environment and facilities
  • Suitability of requested materials
  • Patient confidentiality and scientific/clinical ethics

Access to Monogram's data/materials/services necessary to support collaborations established for each study is based on the conditions of material transfer agreements (MTA) agreeable to Monogram and the collaborator and his/her institution. The specific content of an MTA is developed on a case-by-case basis, but typically includes sections that address the following terms and components of the collaboration:

  • Confidentiality and disclosure of data and related information
  • Use of materials and data
  • Terms and conditions for presentation and publication
  • Acknowledgement and ownership of data/materials/services
  • Inventorship of and rights to intellectual property